Nephropathy remains a major cause of morbidity and a key determinant of mortality in
patients with type 1 or type 2 diabetes mellitus. Research is ongoing to identify biomarkers …

Diabetic nephropathy affects 30–40% of people with diabetes, and is the leading cause of
end‐stage kidney disease. The current treatment paradigm relies on early detection …

Diabetic nephropathy is the leading cause of end-stage renal disease in the United States.
The progression of kidney disease in patients with diabetes can take many years, and …

Diabetic nephropathy (DN) is a well-described complication of diabetes mellitus and the
leading cause of end stage renal disease (ESRD). Although increased albuminuria has …

Diabetic nephropathy (DN), a leading cause of end-stage renal disease (ESRD) affecting∼
20–30% diabetics, is associated with increased cardiovascular mortality. The progression of …

Diabetic nephropathy is the commonest cause of end-stage renal disease in most
developed economies. Current standard of care for diabetic nephropathy embraces …

As the increasing prevalence of diabetes reaches epidemic proportions worldwide, diabetic
nephropathy and associated end‐stage renal failure will be an unavoidable major health …

The kidney is arguably the most important target of microvascular damage in diabetes. A
substantial proportion of individuals with diabetes will develop kidney disease owing to their …

With the global epidemic of type 2 diabetes mellitus, diabetes has become the leading
cause of end stage renal failure (ESRF) in most Western countries. Approximately 20–30 …

Diabetic nephropathy (DN), a persistent microvascular problem of diabetes mellitus is
described as an elevated level of albumin excretion in urine and impaired renal activity. The …